- Published at
- by markets.businessinsider.com
mixed
mixed
Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation
MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical co...